The current focus is on the treatment of multiple myeloma, as well as some other specific blood cancers.

Potential suitability for enrolment in an inobrodib clinical trial is made by oncologists at our collaborative, participating hospitals, and not by CellCentric. Any advice on clinical study options should come from your general practitioner and/or oncologist.